TY - JOUR
T1 - Combined hormonal contraceptives and venous thromboembolism
T2 - Putting the risks into perspective
AU - Raymond, Elizabeth G.
AU - Burke, Anne E.
AU - Espey, Eve
PY - 2012/5/1
Y1 - 2012/5/1
N2 - To date, 13 studies have provided data on the risk of venous thromboembolism associated with combined oral contraceptives containing drospirenone or the norelgestromin-containing contraceptive patch. The studies varied in their conclusions about whether these methods are associated with higher risks than combined oral contraceptives containing other progestins: the primary reported measures of association (adjusted odds ratios, incidence rate ratios, or hazard ratios) ranged from 0.9 to 3.3. All of the studies had weaknesses in population selection, data validity or completeness, or analysis that may have led to biased or spurious findings. Venous thromboembolism is rare; if the contraceptive methods of interest do confer a higher risk of thromboembolism, only an additional 5-10 per 10,000 users per year would be affected. The important message for patients, clinicians, and policy makers is that the benefits of all contraceptive methods markedly outweigh their risks, primarily because they prevent pregnancy, an inherently hazardous condition. Product labels for hormonal contraceptives should emphasize their substantial health benefits and established safety.
AB - To date, 13 studies have provided data on the risk of venous thromboembolism associated with combined oral contraceptives containing drospirenone or the norelgestromin-containing contraceptive patch. The studies varied in their conclusions about whether these methods are associated with higher risks than combined oral contraceptives containing other progestins: the primary reported measures of association (adjusted odds ratios, incidence rate ratios, or hazard ratios) ranged from 0.9 to 3.3. All of the studies had weaknesses in population selection, data validity or completeness, or analysis that may have led to biased or spurious findings. Venous thromboembolism is rare; if the contraceptive methods of interest do confer a higher risk of thromboembolism, only an additional 5-10 per 10,000 users per year would be affected. The important message for patients, clinicians, and policy makers is that the benefits of all contraceptive methods markedly outweigh their risks, primarily because they prevent pregnancy, an inherently hazardous condition. Product labels for hormonal contraceptives should emphasize their substantial health benefits and established safety.
UR - http://www.scopus.com/inward/record.url?scp=84860193714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860193714&partnerID=8YFLogxK
U2 - 10.1097/AOG.0b013e31825194ca
DO - 10.1097/AOG.0b013e31825194ca
M3 - Review article
C2 - 22525916
AN - SCOPUS:84860193714
SN - 0029-7844
VL - 119
SP - 1039
EP - 1044
JO - Obstetrics and gynecology
JF - Obstetrics and gynecology
IS - 5
ER -